目的 探究珍芪補(bǔ)血口服液聯(lián)合多糖鐵復(fù)合物對妊娠期缺鐵性貧血的治療效果。方法 回顧性選取2019年3月— 2020年6月涼山彝族自治州第二人民醫(yī)院收治的112例妊娠期缺鐵性貧血孕婦為研究對象，按照用藥方案的不同將患者分為試驗(yàn)組和對照組，每組各56例。兩組孕婦均遵醫(yī)囑口服維生素C及葉酸片。對照組在此基礎(chǔ)上給予多糖鐵復(fù)合物膠囊口服，0.3 mg/次，1次/d。試驗(yàn)組在對照組的基礎(chǔ)上給予珍芪補(bǔ)血口服液，10 mL/次，2次/d。兩組均治療8周。對比兩組孕婦臨床療效，比較兩組患者治療前后貧血相關(guān)指標(biāo)，包括血紅蛋白（Hb）、血清鐵蛋白（SF）、紅細(xì)胞平均體積（MCV）變化，比較兩組患者治療前后血清轉(zhuǎn)鐵蛋白受體（sTfR）、鐵幼素（HJV）、膜鐵轉(zhuǎn)運(yùn)蛋白1（FPN1）水平及免疫功能相關(guān)指標(biāo)［輔助性T淋巴細(xì)胞（CD4⁺T）、成熟T細(xì)胞（CD3⁺T）、CD4⁺/抑制性T淋巴細(xì)胞（CD8⁺T）］，觀察治療后兩組不良妊娠結(jié)局發(fā)生情況。結(jié)果 治療前，兩組各項(xiàng)指標(biāo)比較差異均無統(tǒng)計(jì)學(xué)意義（P>0.05）。治療后，試驗(yàn)組總有效率為98.21%，明顯高于對照組的87.50%（P<0.05）。治療后兩組患者Hb、SF、MCV、HJV、CD4⁺T、CD3⁺T、CD4⁺/CD8⁺水平較治療前均明顯升高（P<0.05），且試驗(yàn)組明顯高于對照組（P<0.05）。治療后兩組患者血清sTfR、FPN1水平較治療前均明顯降低（P<0.05），且試驗(yàn)組明顯低于對照組（P<0.05）。兩組產(chǎn)婦產(chǎn)后出血及胎兒窘迫、早產(chǎn)、低出生體質(zhì)量兒等不良妊娠結(jié)局發(fā)生率差異無統(tǒng)計(jì)學(xué)意義（P>0.05）。結(jié)論 珍芪補(bǔ)血口服液聯(lián)合多糖鐵復(fù)合物治療妊娠期缺鐵性貧血療效顯著，可有效調(diào)節(jié)孕婦免疫功能，改善貧血癥狀，提高紅細(xì)胞生產(chǎn)速度，且不會增加不良妊娠結(jié)局。

Objective To explore the therapeutic effect of Zhenqi Buxue Oral Liquid combined with polysaccharide iron complex on iron deficiency anemia during pregnancy. Methods Total 112 pregnant women with iron deficiency anemia during pregnancy treated in the Second People's Hospital of Liangshan Yi Autonomous Prefecture from March 2019 to June 2020 were retrospectively selected as the research object. According to the different medication schemes, the patients were divided into experimental group and control group, with 56 cases in each group. Both groups of pregnant women took vitamin C and folic acid tablets orally according to the doctor's advice. On this basis, patients in the control group were given polysaccharide iron complex capsule orally, 0.3 mg/time, once a day. On the basis of the control group, patients in the experimental group were given Zhenqi Buxue Oral Liquid, 10 mL/time, twice a day. Both groups were treated for eight weeks. The clinical efficacy of the two groups of pregnant women was compared, and the anemia related indexes of the two groups before and after treatment, including the changes of hemoglobin (Hb), serum ferritin (SF) and mean red blood cell volume (MCV). The levels of serum transferrin receptor (sTfR), ferritin (HJV), ferroportin-1 (FPN1) and immune function indexes [ auxiliary T lymphocytes (CD4⁺T), mature T cells (CD3⁺T), CD4⁺/inhibitory T lymphocytes (CD8⁺T)] were compared between the two groups before and after treatment. The adverse pregnancy outcomes of the two groups after treatment were observed. Results Before treatment, there was no significant difference in various indexes between two groups (P>0.05). After treatment, the total effective rate of the experimental group was 98.21%, which was significantly higher than 87.50% of the control group (P<0.05). After treatment, the levels of Hb, SF, MCV, HJV, CD4⁺T, CD3⁺T and CD4⁺/CD8⁺ in the two groups were significantly higher than those before treatment (P<0.05), and the levels in the experimental group were significantly higher than the control group (P<0.05). After treatment, the levels of serum sTfR and FPN1 in the two groups were significantly lower than those before treatment (P<0.05), and the levels in the experimental group were significantly lower than those in the control group (P<0.05). There was no significant difference in the incidence of postpartum hemorrhage, fetal distress, preterm birth and low birth weight infants between the two groups (P>0.05). Conclusion Zhenqi Buxue Oral Liquid combined with polysaccharide iron complex is effective in the treatment of iron deficiency anemia during pregnancy. It can effectively regulate the immune function of pregnant women, improve the symptoms of anemia, increase the rate of red blood cell production, and will not increase the adverse pregnancy outcome.

R984

涼山州學(xué)術(shù)和技術(shù)帶頭人培養(yǎng)資金資助項(xiàng)目（涼社辦發(fā)<2018>147號）